Legend Biotech (LEGN) Stock Forecast & Price Target

Compare

510 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LEGN Analyst Ratings

Strong Buy

14 Buy

2 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Legend

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LEGN Stock 12 Month Forecast

Average Price Target

$74.30

▲(111.80% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $74.30 with a high forecast of $94.00 and a low forecast of $37.00. The average price target represents a 111.80% change from the last price of $35.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","95":"$95","44.75":"$44.8","61.5":"$61.5","78.25":"$78.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,44.75,61.5,78.25,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.8,43.04615384615384,47.29230769230769,51.53846153846153,55.78461538461538,60.030769230769224,64.27692307692308,68.52307692307693,72.76923076923077,77.01538461538462,81.26153846153846,85.50769230769231,89.75384615384615,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.8,41.53076923076923,44.26153846153846,46.99230769230769,49.72307692307692,52.45384615384615,55.184615384615384,57.91538461538461,60.646153846153844,63.37692307692308,66.1076923076923,68.83846153846153,71.56923076923077,{"y":74.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.8,38.661538461538456,38.52307692307692,38.38461538461538,38.246153846153845,38.107692307692304,37.96923076923077,37.83076923076923,37.69230769230769,37.55384615384615,37.41538461538462,37.276923076923076,37.13846153846154,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$94.00

Average Price Target$74.30

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eric Schmidt FCA

Cantor Fitzgerald

$55→$66

Buy

88.14%

Upside

Initiated

08/27/25

Legend Biotech assumed with an Overweight at Cantor FitzgeraldLegend Biotech assumed with an Overweight at Cantor Fitzgerald

Jessica Fye

J.P. Morgan

$77→$78

Buy

122.35%

Upside

Reiterated

08/25/25

Legend Biotech price target raised to $78 from $77 at JPMorganLegend Biotech price target raised to $78 from $77 at JPMorgan

Dex Genotek

TR | OpenAI - 4o

$37

Hold

5.47%

Upside

Reiterated

08/20/25

AI Generated ArticleAI Generated Article

Terence Flynn

Morgan Stanley

$81→$83

Buy

136.60%

Upside

Reiterated

08/12/25

Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)Legend Biotech Corp Overweight with price target increase from 81.00 to 83.00.

Gena Wang

Barclays

$94

Buy

167.96%

Upside

Reiterated

08/12/25

Barclays Keeps Their Buy Rating on Legend Biotech (LEGN)

Kostas Biliouris

BMO Capital

$90

Buy

156.56%

Upside

Reiterated

08/12/25

Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating

Mitchell Kapoor

H.C. Wainwright

$75

Buy

113.80%

Upside

Reiterated

08/12/25

Strong Buy Rating for Legend Biotech Driven by CARVYKTI's Market Success and Strategic Expansions

Asthika Goonewardene

Truist Financial

$71

Buy

102.39%

Upside

Reiterated

08/12/25

Analysts Offer Insights on Healthcare Companies: Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN), Privia Health Group (NASDAQ: PRVA) and Legend Biotech (NASDAQ: LEGN)

Yaron Werber

TD Cowen

$62

Buy

76.74%

Upside

Reiterated

08/11/25

TD Cowen Reaffirms Their Buy Rating on Legend Biotech (LEGN)Combined with a progressing oncology and autoimmune pipeline and $1.0B cash runway into profitability in FY26 (Carvykti JV will be profitable by YE25), we reiterate Buy.

Leonid Timashev

RBC Capital

$75→$77

Buy

119.50%

Upside

Reiterated

08/11/25

Legend Biotech (LEGN) Receives a Buy from RBC Capital

Sami Corwin

William Blair

―

Hold

―

Reiterated

08/11/25

Legend Biotech's Hold Rating: Balancing Strong Revenue Growth with Strategic UncertaintiesWe summarize Legend’s financial results compared to our estimates and consensus, and our model updates in exhibits 1 and 2, respectively.

Justin Zelin

BTIG

$91

Buy

159.41%

Upside

Reiterated

08/11/25

Legend Biotech's Strategic Growth and Record Sales Drive Buy Rating

Ziyi Chen

Goldman Sachs

$77.69→$74.51

Buy

112.40%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Goldman Sachs

George Farmer

Scotiabank

$76

Buy

116.65%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Scotiabank

Ashwani Verma

UBS

$60→$54

Buy

53.93%

Upside

Reiterated

07/02/25

Legend Biotech price target lowered to $54 from $60 at UBSLegend Biotech price target lowered to $54 from $60 at UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eric Schmidt FCA

Cantor Fitzgerald

$55→$66

Buy

88.14%

Upside

Initiated

08/27/25

Legend Biotech assumed with an Overweight at Cantor FitzgeraldLegend Biotech assumed with an Overweight at Cantor Fitzgerald

Jessica Fye

J.P. Morgan

$77→$78

Buy

122.35%

Upside

Reiterated

08/25/25

Legend Biotech price target raised to $78 from $77 at JPMorganLegend Biotech price target raised to $78 from $77 at JPMorgan

Dex Genotek

TR | OpenAI - 4o

$37

Hold

5.47%

Upside

Reiterated

08/20/25

AI Generated ArticleAI Generated Article

Terence Flynn

Morgan Stanley

$81→$83

Buy

136.60%

Upside

Reiterated

08/12/25

Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)Legend Biotech Corp Overweight with price target increase from 81.00 to 83.00.

Gena Wang

Barclays

$94

Buy

167.96%

Upside

Reiterated

08/12/25

Barclays Keeps Their Buy Rating on Legend Biotech (LEGN)

Kostas Biliouris

BMO Capital

$90

Buy

156.56%

Upside

Reiterated

08/12/25

Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating

Mitchell Kapoor

H.C. Wainwright

$75

Buy

113.80%

Upside

Reiterated

08/12/25

Strong Buy Rating for Legend Biotech Driven by CARVYKTI's Market Success and Strategic Expansions

Asthika Goonewardene

Truist Financial

$71

Buy

102.39%

Upside

Reiterated

08/12/25

Analysts Offer Insights on Healthcare Companies: Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN), Privia Health Group (NASDAQ: PRVA) and Legend Biotech (NASDAQ: LEGN)

Yaron Werber

TD Cowen

$62

Buy

76.74%

Upside

Reiterated

08/11/25

Leonid Timashev

RBC Capital

$75→$77

Buy

119.50%

Upside

Reiterated

08/11/25

Legend Biotech (LEGN) Receives a Buy from RBC Capital

Sami Corwin

William Blair

―

Hold

―

Reiterated

08/11/25

Justin Zelin

BTIG

$91

Buy

159.41%

Upside

Reiterated

08/11/25

Legend Biotech's Strategic Growth and Record Sales Drive Buy Rating

Ziyi Chen

Goldman Sachs

$77.69→$74.51

Buy

112.40%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Goldman Sachs

George Farmer

Scotiabank

$76

Buy

116.65%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Scotiabank

Ashwani Verma

UBS

$60→$54

Buy

53.93%

Upside

Reiterated

07/02/25

Legend Biotech price target lowered to $54 from $60 at UBSLegend Biotech price target lowered to $54 from $60 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

+2.21%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.21% per trade.

3 Months

xxx

Success Rate

7/15 ratings generated profit

Average Return

+2.90%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +2.90% per trade.

1 Year

Edward TenthoffPiper Sandler

Success Rate

8/15 ratings generated profit

Average Return

-4.46%

reiterated a buy rating 3 months ago

Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of -4.46% per trade.

2 Years

xxx

Success Rate

12/32 ratings generated profit

Average Return

-0.42%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -0.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LEGN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LEGN has received 30 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. LEGN average Analyst price target in the past 3 months is 74.30.

Each month's total comprises the sum of three months' worth of ratings.

LEGN Financial Forecast

LEGN Earnings Forecast

Next quarter’s earnings estimate for LEGN is -$0.04 with a range of -$0.24 to $0.32. The previous quarter’s EPS was -$0.34. LEGN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.10% of the time in the same period. In the last calendar year LEGN has Preformed in-line its overall industry.

LEGN Sales Forecast

Next quarter’s sales forecast for LEGN is $279.46M with a range of $231.00M to $314.19M. The previous quarter’s sales results were $255.95M. LEGN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.87% of the time in the same period. In the last calendar year LEGN has Preformed in-line its overall industry.

LEGN Stock Forecast FAQ

What is LEGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 74.30.

What is LEGN’s upside potential, based on the analysts’ average price target?

Legend Biotech Corporation has 111.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LEGN a Buy, Sell or Hold?

Legend Biotech Corporation has a consensus rating of Strong Buy which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.

What is Legend Biotech Corporation’s price target?

The average price target for Legend Biotech Corporation is 74.30. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $94.00 ,the lowest forecast is $37.00. The average price target represents 111.80% Increase from the current price of $35.08.

What do analysts say about Legend Biotech Corporation?

Legend Biotech Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of LEGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Legend Biotech (LEGN) Stock Forecast & Price Target

LEGN Analyst Ratings

LEGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Legend Biotech

LEGN Analyst Recommendation Trends

LEGN Financial Forecast

LEGN Earnings Forecast

LEGN Sales Forecast

LEGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts